Kriya is a fully integrated gene therapy company focused on designing and developing transformative gene therapies for highly prevalent serious diseases.
Kriya's mission is to expand the reach of gene therapy to address highly prevalent diseases affecting millions of patients.
Kriya Therapeutics was founded in 2019 by Shankar Ramaswamy, Roger Jeffs and John Fraser Wright. The company is headquartered in Palo Alto, California, with an office in Morrisville, NC.
Kriya leverages its proprietary computational engine, in-house manufacturing infrastructure, and integrated design platform to engineer products with the potential to transform the treatment of a broad range of diseases.
Kriya has established an ecosystem for delivering best-in-class technologies and medicines, with core business units in technology, manufacturing, R&D, and therapeutics. Kriya’s product pipeline addresses diseases of high unmet need with therapeutic area divisions in ophthalmology, oncology, rare disease, and chronic diseas.
Kriya has also scaled SIRVE™, its machine learning-enabled technology and cloud computing architecture, to support the integration of large datasets generated by the company’s high throughput screening, next generation sequencing, and algorithmic data mining platforms.
Kriya is backed by Patient Square Capital, QVT, Dexcel Pharma, Bluebird Ventures, Foresite Capital, Woodline Partners LP, Amplo, CAM Capital, JDRF T1D Fund, Lightswitch Capital, and others. The company raised $270M in Series C round on May 16, 2022. This brings Kriya's total funding to $450.5M to date.